Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GPC Biotech has initiated a phase I study evaluating the company's lead drug candidate, satraplatin, in combination with Roche's chemotherapeutic Xeloda in patients with advanced solid tumors.
Subscribe to our email newsletter
The primary objective of this study is to determine the maximum tolerated dose for satraplatin in combination with Xeloda in patients with advanced solid tumors. The trial is expected to enroll up to 24 patients.
The phase I study is an open label study being conducted at Northwestern University Medical Center in Chicago under the direction of Dr William Gradishar, director of breast medical oncology.
Xeloda is an oral form of 5-FU, a marketed chemotherapy treatment that is used to treat various cancers, including metastatic breast and colorectal cancers.
“Combinations of intravenous 5-FU and certain marketed platinum compounds have shown activity in a number of cancers. I am excited about the potential that the combination of satraplatin and Xeloda may hold. This oral-oral regimen, if effective, may offer doctors an important new, well tolerated and convenient treatment option for patients with a variety of cancers,” commented Dr Gradishar.